Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology

The current control of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease is very low and this is associated with an increase of cardiovascular outcomes. In addition, the latter this happens, the risk will be greater. This is mainly due to an insufficient...

Descripción completa

Detalles Bibliográficos
Autores: Escobar, C, Anguita, M, Arrarte, V, Barrios, V, Cequier, A, Cosin-Sales, J, Egocheaga, I, de Sa, EL, Masana, L, Pallares, V, de Isla, LP, Pinto, X, Juanatey, JRG, Zamorano, JL
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p10872
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/10872
Access Level:acceso abierto
Palabra clave:Ischemic heart disease
LDL-cholesterol
Secondary prevention
Lipid-lowering therapy
Descripción
Sumario:The current control of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease is very low and this is associated with an increase of cardiovascular outcomes. In addition, the latter this happens, the risk will be greater. This is mainly due to an insufficient use of the lipid-lowering therapy currently available. In fact, with current treatments (statins, ezetimibe and PCSK9 inhibitors), the majority of patients in secondary prevention should achieve low-density lipoprotein cholesterol goals. For these reasons, in this manuscript promoted by the Spanish Society of Cardiology we propose three simple and feasible decision-making algorithms that include the majority of clinical scenarios among patients with ischemic heart disease, with the double aim of attaining therapeutic goals in the majority of patients as soon as possible; in secondary prevention the magnitude of the benefit is risk- and time-dependent. (C) 2019 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.